On August 31, 2026 Defence Therapeutics Inc. ("Defence" or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum technology, reported the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and beta-emitting radioisotopes. This expansion is to broaden the capability of the Accum platform, which is designed to facilitate intracellular transport for enhanced payload delivery.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The initiative reflects Defence’s growing strategic focus on radiopharmaceuticals, a rapidly advancing area of precision oncology where the Company believes Accum has significant potential to create novel products and improve existing ones. Accum improves how well radioactive drugs get inside cancer cells, allowing more of the cancer-killing payload to reach its target and destroy the tumor from within. Defence is accelerating the development of its internal radiopharmaceutical program to further evaluate this potential and advance Accum-enabled radio-immunoconjugates candidates toward clinical development.
Defence’s radiopharmaceuticals program will evaluate alpha emitters, such as Actinium-225, for their high-energy, short-range localized cellular damage. Concurrently, the Company will evaluate beta emitters, such as Lutetium-177, for their medium-energy, longer-range penetration profiles, allowing for a comprehensive comparison of how different isotope properties are enhanced by the Accum platform.
The expanded program is designed to generate comparative pharmacology, efficacy and safety data across both isotope classes while further establishing Accum as a versatile intracellular delivery platform for a variety of radioisotope payloads. The ongoing preclinical programs are focused on the Accum platform’s core mechanism to optimize accumulation in target cells and reduce off-target toxicity. By building out the preclinical data, Defence aims to deliver clinical candidates and strengthen the Company’s growing pipeline of proprietary radiopharmaceutical assets.
"By expanding our platform development to evaluate both alpha and beta isotopes as distinct pathways, we can comprehensively analyze the compatibility of Accum with different payload profiles," says Dr. Ryan Simms, Defence’s newly instated Chief Operating Officer and Head of Radiopharmaceuticals Program.
"This parallel development program gives Defence the data required to optimize Accum-enhanced radio-immunoconjugates for diverse candidate selections and to establish Accum as a technology capable of enhancing the next generation of targeted therapies across multiple therapeutic modalities," says Dr. Amie Phinney, President and Chief Executive Officer of Defence Therapeutics.
(Press release, Defence Therapeutics, AUG 31, 2026, View Source;utm_medium=rss&utm_campaign=defence-therapeutics-expands-radiopharmaceutical-development-strategy-with-alpha-and-beta-emitter-programs [SID1234670442])